AU2009297091B2 - Compositions and methods for achieving sustained therapeutic drug concentrations in a subject - Google Patents

Compositions and methods for achieving sustained therapeutic drug concentrations in a subject Download PDF

Info

Publication number
AU2009297091B2
AU2009297091B2 AU2009297091A AU2009297091A AU2009297091B2 AU 2009297091 B2 AU2009297091 B2 AU 2009297091B2 AU 2009297091 A AU2009297091 A AU 2009297091A AU 2009297091 A AU2009297091 A AU 2009297091A AU 2009297091 B2 AU2009297091 B2 AU 2009297091B2
Authority
AU
Australia
Prior art keywords
days
administering
prodrug
once
irinotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009297091A
Other languages
English (en)
Other versions
AU2009297091A1 (en
Inventor
Tamra L. Barker
Michael A. Eldon
Shibani S. Harite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of AU2009297091A1 publication Critical patent/AU2009297091A1/en
Application granted granted Critical
Publication of AU2009297091B2 publication Critical patent/AU2009297091B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009297091A 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject Active AU2009297091B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US61/099,516 2008-09-23
US10693108P 2008-10-20 2008-10-20
US61/106,931 2008-10-20
US17343309P 2009-04-28 2009-04-28
US61/173,433 2009-04-28
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (2)

Publication Number Publication Date
AU2009297091A1 AU2009297091A1 (en) 2010-04-01
AU2009297091B2 true AU2009297091B2 (en) 2015-03-05

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009297091A Active AU2009297091B2 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Country Status (21)

Country Link
US (3) US8906353B2 (enExample)
EP (1) EP2349346B1 (enExample)
JP (3) JP2012503602A (enExample)
KR (1) KR20110063457A (enExample)
CN (1) CN102164617A (enExample)
AU (1) AU2009297091B2 (enExample)
CA (1) CA2736939C (enExample)
CY (1) CY1122208T1 (enExample)
DK (1) DK2349346T3 (enExample)
ES (1) ES2744975T3 (enExample)
HR (1) HRP20192120T1 (enExample)
HU (1) HUE047352T2 (enExample)
IL (1) IL211888A (enExample)
LT (1) LT2349346T (enExample)
MX (1) MX2011003063A (enExample)
PL (1) PL2349346T3 (enExample)
PT (1) PT2349346T (enExample)
RS (1) RS59607B1 (enExample)
SI (1) SI2349346T1 (enExample)
SM (1) SMT201900609T1 (enExample)
WO (1) WO2010036335A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59607B1 (sr) 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
WO2014085571A1 (en) * 2012-11-28 2014-06-05 Nektar Therapeutics Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
CA3026144A1 (en) 2016-06-02 2017-12-07 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
US11253603B2 (en) * 2018-09-17 2022-02-22 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
US20240156808A1 (en) * 2021-02-23 2024-05-16 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112088A1 (en) * 2003-09-17 2005-05-26 Xuan Zhao Multi-arm polymer prodrugs
US20070197575A1 (en) * 2006-02-09 2007-08-23 Hong Zhao Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CN101199857A (zh) * 2007-12-12 2008-06-18 中国药科大学 mPEG-PLA-喜树碱类药物的结合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
IL117684A (en) 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
AU772074B2 (en) 1999-04-28 2004-04-08 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
WO2002008789A2 (en) 2000-07-21 2002-01-31 Services Petroliers Schlumberger Nuclear magnetic resonance methods for extracting information about a fluid in a rock
JP2004514701A (ja) 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
JP2005508365A (ja) 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル，コーポレイション プロテインキナーゼｃインヒビターのポリマー結合体
ES2284959T3 (es) 2001-10-30 2007-11-16 Nektar Therapeutics Al, Corporation Conjugados polimericos solubles en agua de acido retinoico.
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
CN101843904A (zh) 2002-06-06 2010-09-29 华盛顿大学 使用青蒿素样化合物预防或延缓癌症显现的方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CA2642717C (en) * 2006-02-17 2015-08-18 Novacea, Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP2109448B1 (en) * 2007-02-09 2013-09-11 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
RS59607B1 (sr) 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112088A1 (en) * 2003-09-17 2005-05-26 Xuan Zhao Multi-arm polymer prodrugs
US20070197575A1 (en) * 2006-02-09 2007-08-23 Hong Zhao Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CN101199857A (zh) * 2007-12-12 2008-06-18 中国药科大学 mPEG-PLA-喜树碱类药物的结合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLEGRINI, G. et al: British Journal Of Cancer, Nature Publishing Group, London, GB, vol. 98, no. 8, 1 April 2008, pages 1312-1319 *
LALLOO, A. et al: Journal Of Controlled Release, Elsevier, Amsterdam, NL, vol. 112, no. 3, 30 May 2006, pages 333-342 *
ROWINSKY, E.K. et al, "A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1- Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies", Journal of Clinical Oncology 2003 (21) 1, pages 148-157. *

Also Published As

Publication number Publication date
US20110269789A1 (en) 2011-11-03
CN102164617A (zh) 2011-08-24
EP2349346A1 (en) 2011-08-03
CY1122208T1 (el) 2020-11-25
CA2736939A1 (en) 2010-04-01
HUE047352T2 (hu) 2020-04-28
WO2010036335A1 (en) 2010-04-01
US10525051B2 (en) 2020-01-07
MX2011003063A (es) 2011-04-21
US9801873B2 (en) 2017-10-31
PL2349346T3 (pl) 2020-03-31
HRP20192120T1 (hr) 2020-02-21
IL211888A (en) 2015-08-31
US20150087668A1 (en) 2015-03-26
ES2744975T3 (es) 2020-02-27
US8906353B2 (en) 2014-12-09
EP2349346B1 (en) 2019-08-28
LT2349346T (lt) 2019-09-25
SI2349346T1 (sl) 2019-12-31
AU2009297091A1 (en) 2010-04-01
PT2349346T (pt) 2019-10-24
JP2015034180A (ja) 2015-02-19
KR20110063457A (ko) 2011-06-10
JP2016216510A (ja) 2016-12-22
US20180028525A1 (en) 2018-02-01
DK2349346T3 (da) 2019-10-07
RS59607B1 (sr) 2020-01-31
SMT201900609T1 (it) 2020-01-14
IL211888A0 (en) 2011-06-30
CA2736939C (en) 2021-09-14
JP6076317B2 (ja) 2017-02-08
JP2012503602A (ja) 2012-02-09

Similar Documents

Publication Publication Date Title
US10525051B2 (en) Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
Li et al. Current drug research on PEGylation with small molecular agents
Venditto et al. Cancer therapies utilizing the camptothecins: a review of the in vivo literature
Manjappa et al. Polymeric mixed micelles: improving the anticancer efficacy of single-copolymer micelles
JP2022166327A (ja) 癌の治療法
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
AU2019383466B2 (en) Therapeutic dendrimer
WO2019204799A1 (en) Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
KR101678881B1 (ko) 부작용을 가지지 않는 항암제
HK1155083B (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
HK1155083A (en) Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
AU2013205079B2 (en) Treatment of cancer
Connolly et al. An overview of DNA topoisomerase I inhibitors under development
Kundu et al. 5 Heparin and Its
HK1214145B (en) Anticancer agent having no side effects
Van Cuong et al. Chemotherapy of Nano-Sized Camptothecin-Derived Drugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)